Aytu BioPharma第四年在德洛伊特公司的快速500排名第380位,EBITDA增长162%。 Aytu BioPharma ranks 380th on Deloitte's Fast 500 for the fourth year, with a 162% EBITDA increase.

Aytu BioPharma是一家美国制药公司,连续第四年在德勤技术快速500TM名单中排名第380位,承认北美增长最快的技术和生命科学公司。 Aytu BioPharma, a US pharmaceutical company, ranked 380th on Deloitte's Technology Fast 500™ list for the fourth consecutive year, recognizing the fastest-growing technology and life sciences firms in North America. 该公司经调整的EBITDA增加了162%,达到2024年920万美元。 The company saw a 162% increase in adjusted EBITDA to $9.2 million in fiscal 2024. Aytu专门从事新疗法的商业化,包括ADHD和其他条件的治疗。 Aytu specializes in commercializing novel therapeutics, including treatments for ADHD and other conditions.